A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

NCT01853852 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: GR181413A/AT1001 solution
DRUG: GR181413A/AT1001 capsule
OTHER: Potable water
DRUG: Placebo capsule

Sponsor

Amicus Therapeutics